companiesCompany
InnoCare Pharma
aka 诺诚健华
InnoCare developed orelabrutinib, a selective BTK-blocking pill approved in China for chronic lymphocytic leukaemia and mantle cell and marginal zone lymphomas.
Overview
Orelabrutinib (Yinuokai) approved 2020 and 2023; the pan-TRK inhibitor zurletrectinib, the BCL2 inhibitor mesutoclax, an ICP-B02 CD20 x CD3 bispecific and a TYK2 programme. Co-founded by Jisong Cui and structural biologist Yigong Shi.
Headquarters
Beijing, CN
Scorecard
All companies#91of 680 companies, score 30
- approved products +6
- targets +2
- modalities +2
- regions +1
- registry trials +19
1 approved, 0 in phase 3, 0 earlier, 1 targets, 87 registry studies. Formula on the scorecards page.
Type
biotech · 9969.HK / 688428.SS
Stage
Public
Website
Founded
2015
Pages like this
not linked directly; found by shared links- CancerMantle cell lymphoma